SCHEDULE: Forbion Funds Divest Entire Astria Therapeutics Stake

Forbion Growth III PA B.V. and related entities report 0% beneficial ownership in Astria Therapeutics, Inc. common stock.

Summary

• ForGrowth III PA B.V., Forbion Growth Opportunities Fund III Cooperatief U.A., and Forbion Growth III Management B.V. (collectively, the "Reporting Persons") have filed an amendment to their Schedule 13G.
• The Reporting Persons now beneficially own 0.0% of Astria Therapeutics, Inc.'s common stock.
• As of the filing date, none of the Reporting Persons may be deemed to beneficially own any shares of Common Stock of Astria Therapeutics, Inc.
• The event requiring this filing occurred on October 16, 2025, indicating the date when their beneficial ownership dropped below the reporting threshold.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative as a group of institutional investors has fully divested their stake in Astria Therapeutics, Inc., which could imply a lack of confidence or a strategic exit. While a routine disclosure, the complete exit of an investor is generally not a positive signal for the company.

Negatives

• The Reporting Persons, a group of Netherlands-based entities, no longer hold any beneficial ownership in Astria Therapeutics, Inc., indicating a complete divestment of their previously held stake.
• The exit of an institutional investor could be perceived as a negative signal regarding the company's future prospects or current valuation.

Risks

• Potential negative investor sentiment due to the complete divestment by a group of institutional investors.
• Possible impact on share price if the market interprets the divestment as a lack of confidence in Astria Therapeutics, Inc.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Astria Therapeutics, Inc.'s future performance or operations.

Industry Context

This filing represents a routine disclosure of a change in institutional ownership, common in the biotechnology sector. The divestment by a venture capital-backed group like Forbion could reflect a strategic portfolio decision or a re-evaluation of the investment thesis for Astria Therapeutics, Inc. It is a standard part of the investment lifecycle for such funds.

Stakeholder Impact

• Shareholders of Astria Therapeutics, Inc. may react negatively to the news of a significant institutional investor divesting its entire stake, potentially leading to downward pressure on the stock price.
• The company's perception among potential future investors might be affected by the exit of a known investment group.

Key Dates

Keywords

Astria Therapeutics, Forbion, Schedule 13G, beneficial ownership, common stock, divestment, institutional investor, equity stake